A r t i c l e s
Common immune-mediated diseases such as IBD have a genetic basis. However, until recently, identifying disease susceptibility genes has been challenging for common, polygenic disease 5, 6 . With the development of HapMap and GWAS technology, the number of bona fide risk loci that have been identified and replicated for complex trait genetics in general, and for IBD in particular, has markedly increased. In Crohn's disease, individual GWAS scans and follow-up meta-analyses have identified >71 susceptibility loci and have provided insights beyond the two loci established before the GWAS era 7, 8 . Similarly, in ulcerative colitis, GWAS efforts have identified 47 susceptibility loci 9, 10 and, after accounting for the many alleles associated with both diseases, 99 distinct associations have been documented for IBD. Although these findings have clarified disease pathways, the common SNPs identified are generally of modest effect and explain only ~23% of the overall variance in Crohn's disease risk. Moreover, most of the associated variants do not have known or obvious function, and many implicate regions with multiple genes, limiting biological extrapolation.
SNPs implicated by GWAS are tightly correlated with other SNPs in the region and are probably in linkage disequilibrium (LD) with the causal variant rather than causal themselves. A complete catalog of all variation is required in the search for causal variants 11, 12 . However, even in denser reference data from the 1000 Genomes Project, most GWAS hits are not correlated with an obvious functional variant and therefore do not conclusively implicate a unique gene. If independently associated rare coding variation is discovered in a gene within a region implicated by GWAS, the gene harboring such variants is directly implicated. Furthermore, additional heritability can be explained and specific alleles identified for direct functional experimentation. In Crohn's disease, multiple independent associated alleles have been documented at NOD2 and IL23R 13, 14 . Exhaustive sequencing of genomic regions has recently become possible for the first time with the advent of next-generation sequencing (NGS) technologies. Growing collections of genome sequences through international efforts like the 1000 Genomes Project are driving the development of laboratory study designs and analytic methods for using large-scale genomic sequencing in human genetic discovery 15 .
Targeted sequencing of pooled samples allows researchers to efficiently and cost-effectively capture all variation in a limited target region that has been selectively amplified in multiple DNA samples 16, 17 . This approach allows efficient use of NGS technologies, which generate billions of base pairs per experimental unit yet introduce challenges in data processing and analysis, for the discovery of new variants and assess their potential association with disease. We describe here a pooled NGS study of 350 Crohn's disease cases and 350 controls across coding exons of 56 genes contained in regions of confirmed association with Crohn's disease 7 , and we introduce new SNP calling methods for pooled targeted sequencing projects implemented in the software Syzygy. We further evaluated new, potentially functional rare variants identified in the survey in nine independent case-control series, confirming a role for functional, rare variants in CARD9, NOD2, IL23R and IL18RAP and identifying others in MUC19, CUL2, PTPN22 and C1orf106 that were significantly associated with IBD. The results lend further support to an emerging paradigm in both rare diseases (Hirschsprung's disease and Bardet-Biedl syndrome) and common phenotypes (serum lipids, QT-interval and height and type 1 diabetes) in which both common, low-penetrance and rarer, often higher-penetrance alleles exist in the same gene. They also suggest that deep sequencing of regions implicated by GWAS may be effective in increasing knowledge about the heritability of specific functional alleles in complex disease 16, [18] [19] [20] [21] .
RESULTS

Discovery of new variants using pooled sequencing
We selected 350 Crohn's disease cases and 350 healthy controls of European ancestry from among samples collected by the NIDDK IBDGC with genome-wide SNP data 14, 22 . We pooled samples in batches of 50 cases or 50 controls matched for European ancestry using GWAS data. One pool of 50 cases was drawn from self-reported and empirically confirmed (by GWAS data 22 ) Jewish ancestry and was matched with one pool of 50 equivalently defined Jewish controls. The remaining pools of cases and controls were selected from the non-Jewish European-American samples. Samples were pooled only after two rounds of quantification and normalization to ensure that the initial DNA pool accurately reflected sample allele frequencies. For each pool, we carried out PCR amplification to capture the 107.5-kb target region, which included 645 nuclear-encoded exons ( Supplementary Tables 1 and 2) . We amplified each sample in 593 PCR reactions. The successful PCR amplicons were combined in equimolar amounts, concatenated and sheared to construct libraries. The 14 libraries were sequenced using Illumina Genome Analyzer flow cells, with one pool per lane (see Online Methods; Fig. 1a) . High-throughput sequencing yielded large amounts of high-quality data for each pool. We captured 91% of our nuclear target regions at ≥100× coverage and achieved 1,500× median coverage per pool (corresponding to 30× per sample or 15× per individual chromosome; Supplementary Fig. 1 ).
We next aimed to identify rare and low-frequency single-nucleotide variants (SNVs) in the pooled samples. We developed a variant calling method, Syzygy, to accommodate the specific pooled study design Fig. 3a,b) , suggesting that we can address the contribution of rare and low-frequency polymorphisms in GWAS loci to IBD. OR, odds ratio. 23 . To confirm this, we selected a random subset of 137 high-confidence functional nonsynonymous, nonsense and putative splice-variant SNPs for Sequenom iPLEX genotyping of all samples in the sequenced pools and validated 91.2% of them (Fig. 1a) . Using , where n denotes the number of chromosomes and Nbases represents the targeted bases, or the rate observed directly in 1000 Genomes Pilot 3, we would expect to see ~470 variants across the successfully queried target. Sensitivity for singletons, however, is incomplete at the lower end of coverage in our experiment ( Supplementary Fig. 1 ) and accounts for the modest deficit in our study. A challenge in pooled genotyping or sequencing experiments is accurate recovery of allele frequencies. We were surprised to observe a strong correlation between genotype frequencies and frequencies estimated for sequence data (r 2 ≈ 0.99) using the method in Syzygy, suggesting that accurate quantification of DNAs in the pooling steps led to experimental recovery of the pool composition. We also observed a strong correlation between the case-control test statistic estimated with the pooled data and the test statistic in the genotype data (r 2 ≈ 0.925; Supplementary Fig. 2) .
To test the role of these rare variants, we identified all nonsynonymous, nonsense or splice-site variants that occurred in two or more copies up to a frequency of 5%, for a total of 115 variants (Supplementary Table 3 ). Excluding known GWAS-associated low-frequency coding variants at NOD2, IL23R and LRRK2-MUC19, we carried out follow-up genotyping for 70 of these markers in nine independent case-control series totaling 16,054 Crohn's disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls. These included (i) samples from the Prospective Registry in IBD Study at MGH (PRISM); (ii) samples assembled from throughout North America and Australia by the NIDDK IBDGC; (iii) an Italian-Dutch case-control sample; (iv) Crohn's and Colitis Foundation of America (CCFA) Repository Collection; (v) Swedish samples; (vi) Cedars samples; (vii) German samples and Immunochip genotype data provided by (viii) the International IBD Genetics Consortium and (ix) UK IBD Genetics Consortium (rare coding variants discovered in this study contributed to the Immunochip design; Fig. 1a) . Samples i and iii-vii were genotyped for sets of markers using Sequenom iPLEX. Sample ii genotyping was done as part of a larger NIDDK IBDGC Illumina GoldenGate study. Because of design constraints and assay failures, not all markers were examined in all nine follow-up sample sets (see Supplementary Methods for details of follow-up genotyping). We demonstrate that the current study design is well positioned to address the overall contribution of variants in coding regions of GWAS loci to IBD (Fig. 1b, Supplementary Fig. 3 and Supplementary Methods).
The few nonreference alleles expected for many of these variants in each substudy precludes the use of asymptotic statistics common to most association studies. Population structure is probably an even more substantial problem at low frequencies, demanding a stratified analysis retaining strict population case-control matching. Therefore, we used a mega-analysis of rare variants (MARV) that provides a permutation-based estimate of significance, constraining all permutations to be within each subgroup and thus accommodating arbitrary numbers of sample subsets of diverse population and case-control origin without power loss for single-marker and group-marker analysis (see Online Methods). Given a target set of 70 variants, we would expect <1 SNP to exceed P < 0.01 by chance in the follow-up analyses and define traditional experiment-wise significance to be P = 0.0007. As we explored both Crohn's disease and ulcerative colitis in follow-up studies, our primary analysis compared all IBD (Crohn's disease and ulcerative colitis) cases versus controls to maximize power for genes in which the same common variants have been conclusively associated with both diseases with similar effect (such as CARD9). For genes specifically associated with Crohn's disease only (such as NOD2), the ulcerative colitis group was combined with controls (for details, see ref. 10 ).
New protective splice variant in CARD9
CARD9 is associated with both Crohn's disease and ulcerative colitis risk, with a common coding variant (rs4077515 creating substitution p.S12N with both alleles of roughly equal frequency) that represents a 'typical' GWAS hit (odds ratio (OR) ≈ 1.2 in both diseases) 8, 9 . In the pooled sequencing, we identified a splice-site variant in CARD9 ( Fig. 2 and Supplementary Fig. 4 ) that altered the first base after exon 11 in six controls and zero cases, suggesting a potentially strong protective effect. Follow-up analyses confirmed a highly significant association (P < 10 −16 ), with the allele appearing in about 0.20% of cases and 0.64% of controls (OR ≈ 0.3; Table 2 and Supplementary Table 4) . Figure 2 CARD9 protective splice-site variant and predicted transcript. Splice-site variant IVS11+1C>G (OR = 0.29), conferring protection against Crohn's disease with predicted transcript. This hypothetical transcript has been observed in spleen, lymph-node and PBMC-derived cDNA libraries. We predict exon 11 to be skipped and the alternative transcript to include exon 9 mRNA sequence continuing to exon 12, including 21 amino acids before reaching a premature stop. 
A r t i c l e s
Although skipping exon 11 places translation out of frame, we predict that the resulting transcript would escape nonsense-mediated decay as premature truncation occurs close to the final splice junction in exon 12. Indeed, this hypothetical transcript ( Fig. 2 and Supplementary  Fig. 4 ) has been observed in cDNA libraries derived from spleen, lymph node and peripheral blood mononuclear cells (PBMCs). Notably, this rare protective variant occurs on a haplotype carrying the risk allele at rs4077515, indicating not only that the two associations are independent but also that the splice variant completely eliminates the risk normally associated with the common haplotype. Because the Crohn's disease risk allele at rs4077515 has been associated with higher expression of CARD9, a consistent allelic series may exist if the splice variant is substantially lower or nonfunctional and therefore highly protective.
Rare risk variants in NOD2
NOD2 encodes a member of a family of human cytosolic, non-Toll/IL-1 receptor (TIR) neuronal apoptosis inhibitor protein (NACHT)-leucine-rich repeat (LRR) proteins 24 first implicated in Crohn's disease 13, 25 and later discovered to be involved in Blau syndrome 26 . The three previously known causal mutations, R702W, G908R and fs1007insC, are in the LRR domain of NOD2, whereas the mutations identified in Blau syndrome are in the highly conserved NACHT nucleotide-binding domain. We identified five distinct rare variants (R311W, S431L, R703C, N852S and M863V), and several others in LD with one of these, that are independently associated with Crohn's disease risk ( Table 2 and Supplementary Table 4 ). The S431L (P = 0.0004) (and the rarer V793M contained on a subset of S431L haplotypes), R703C (P = 2.3 × 10 −5 ) (previously suggested in one study to be associated 27 ) and N852S (P = 1.1 × 10 −6 ) variants are found on distinct haplotypes that do not contain the known causal mutations R702W, G908R and fs1007insC (Fig. 3a,b) and are thus completely independent risk variants. R311W shares a subset of haplotypes with R703C (Fig. 2) ; however, conditional analysis and haplotype testing indicate that both alleles probably contribute independently to risk (Supplementary Table 5 ). M863V is a rarer variant that has arisen on the haplotype background of fs1007insC, and although the risk estimate of M863V+fs1007insC (OR = 4.02 (95% CI = 2.8-5.7)) is higher than the risk attributable to fs1007insC alone (OR = 3.16 (95% CI = 2.9-3.4)), We identified IVS11+1G>C to be protective against IBD with an estimated OR of 0.29 (four-fold protective effect). Five independent rare variants in NOD2 were associated with Crohn's disease, including R311W, R703C, S431L+V793M, N852S and M863V+fs1007insC. Additional variants conferring protection against IBD were identified in IL23R and CUL2, and risk missense variants were identified in IL18RAP, C1orf106, MUC19 and PTPN22. 1 0 7 0 VOLUME 43 | NUMBER 11 | NOVEMBER 2011 Nature GeNetics A r t i c l e s the low frequency of M863V makes its functionality unclear. Thus, in later calculations of variance explained, we did not count this as an additional risk factor.
Functional assessment of additional associated alleles in NOD2
Through assays to identify the effect of the mutations on NOD2 intracellular localization, we found that the S431L mutant and the well-studied insertion mutant (fs1007insC) did not localize to the membrane area, in contrast with N852S (Fig. 4) . We next determined whether the NOD2 mutants S431L and N852S activated NF-κB in response to the NOD2 ligand muramyl dipeptide (MDP). HEK293T cells were transfected with the point mutants, wild-type NOD2 and the well-studied fs1007insC mutant (Fig. 4) . Western blot analysis showed that the point mutations did not affect expression compared with the wild-type protein (Fig. 4) . As published earlier 28, 29 , the fs1007insC mutant did not induce NF-κB activation after MDP stimulation. The MDP-induced NF-κB activation was also impaired in the presence of S431L and N852S (Fig. 4) . Together, these results indicate that the N852S alteration in the LRR domain may perturb MDP recognition without affecting NOD2 intracellular localization, similarly to the common R702W and G908R alterations 28 . This contrasts with the fs1007insC mutation, which also affects targeting of NOD2 to the membrane area. The S431L variant is in the nucleotide-binding domain of the protein and impairs both localization and MDP-induced NF-κB activation. These findings are similar to earlier studies demonstrating that critical residues in the nucleotide-binding domain region attenuate MDP-dependent NF-κB activation 29 . Further studies are needed to determine the instructive role of NOD2 mutants in coordinating autophagy, control of cellular stress signals and adaptive immune responses.
N852S and M863V variants are more common in Ashkenazi Jewish individuals
The highest reported prevalence of Crohn's disease is in subjects of Ashkenazi Jewish descent, with two to four times higher prevalence than non-Jewish populations 30 . An earlier study 31 has screened the NOD2 gene for rare variants and identified five previously unreported changes (D113N, D357A, I363F, L550V and N852S). N852S occurs only in Ashkenazi Jewish individuals and has been proposed to predispose disease, with seven transmissions and only one nontransmission from heterozygous parents to affected offspring in an Ashkenazi Jewish family collection, concordant with the case-control observations in this study. In our study, Ashkenazi Jewish individuals had a much higher frequency of both N852S and M863V (4% and 2%, respectively, in Ashkenazi Jewish Crohn's disease cases, and 0.5% for N852S and M863V in non-Ashkenazi Jewish Crohn's disease cases). This accounts for the greater incidence of these alleles in the first replication column of Table 2 , as NIDDK studies in particular had a specific and significant Ashkenazi Jewish collection.
We examined the haplotype carrying N852S in Ashkenazi Jewish individuals (determined given the existence of two homozygote cases) and in non-Ashkenazi Jewish individuals in the subset of samples with existing GWAS genotype data 8, 9, 14, 22 . We found that the N852S variant in Ashkenazi individuals lies on a unique extended haplotype of several megabases (≥2 Mb to the left and right). However, the N852S variant in non-Ashkenazi Jewish individuals does not share the extended background haplotype. In Ashkenazi individuals, the average shared distance between a pair of N852S chromosomes is ≥4 Mb, whereas in non-Ashkenazi individuals, the average shared distance between a pair of N852S chromosomes is 0.5 Mb (Supplementary Fig. 5) , suggesting that the variant is reasonably old but that a single copy was stochastically enriched in the recent Ashkenazi bottleneck ~25 generations ago.
Rare protective variants in IL23R
We also identified significant protective effects of substitutions G149R (P = 3.2 × 10 −4 ) and V362I (P = 1.2 × 10 −5 ) in IL23R. This confirms recent findings 32 and indicates that each of these variants have a protective effect equivalent to that of the more common R381Q substitution ( Table 2 and Supplementary Table 4 ), although they arose on different haplotype backgrounds and are not in LD with R381Q. Despite the large follow-up sample size (n = 31,747), we did not find evidence for a protective effect of the previously reported R86Q variant (P = 0.94). IL23R signaling is attenuated in T helper type 17 (T H 17) cells generated from healthy subjects carrying the R381Q substitution, leading to a decrease of IL-17A secretion in response to IL-23, and indicating that R381Q is associated with reduced T H 17 a b (R311W, S431L, R702W , R703C, V793M, N852S, M863V, G908R and fs1007insC). S431L and V793M are in tight LD and we regard this as one unit (S431L V793M). R703C is at a higher frequency than R311W although they share haplotypes. Conditional analysis (supplementary table 3) demonstrates independent contributions. M863V lies on background haplotype of fs1007insC.
A r t i c l e s responses 33 . In addition, recent studies have highlighted a role for IL-23 in T H 17 cell lineage commitment without TGF-β. This alternate mode of T H 17 differentiation, dependent on IL23R expression, seems to have a greater pathogenic role than TGF-β−induced T H 17 differentiation, highlighting the value of discovering protective variants in autoimmunity 34 . Future therapies for autoimmune disease should consider the phenotypic characteristics of pathogenic T H 17 cells generated without TGF-β, and their signaling pathways as possible targets.
Additional rare risk and protective variants
Although Crohn's disease and ulcerative colitis do not share an association with the common variant rs2058660 in IL18RAP (minor allele frequency (MAF) = 0.23, OR ≈ 1.19 for Crohn's disease, chr2:102.17-102.67 Mb), an association of rs2058660 with celiac disease has recently been documented 35 . We identified a rare risk missense variant, V527L (MAF = 0.003), in IL18RAP with an estimated minor allele OR of 2.79 for Crohn's disease. In addition, a low-frequency missense variant, Y333F (MAF = 0.008), in C1orf106 was associated with risk of both Crohn's disease and ulcerative colitis.
A common CUL2 variant (rs12261843, MAF = 0.30, OR ≈ 1.15) is associated with both Crohn's disease and ulcerative colitis risk 8, 9 . In the pooled sequencing experiment, we identified a splice-site variant in CUL2 altering a nucleotide five bases downstream of exon 17 with an estimated OR of 0.72 in the follow-up samples (MAF = 0.007). Notably, several members of the ubiquitin proteosome are present in the autophagy interaction network, including CUL2, suggesting cross-talk between these processes in intracellular quality control and immunity 36 .
A common missense variant (risk allele frequency = 0.90; OR = 1.31, rs2476601) in PTPN22 is associated with Crohn's disease 7, 8 , type 1 diabetes 37 , rheumatoid arthritis 38 and vitiligo 39 . In this instance, the direction of association differs in different diseases, with the minor allele (Trp) strongly associated with type 1 diabetes, rheumatoid arthritis and vitiligo but highly protective against Crohn's disease. Analysis of rare variants in IBD cases versus healthy controls showed a modest risk effect (P = 0.00026, minor allele OR = 1.6) for a rare (MAF = 0.003) PTPN22 missense variant (H370N). Ongoing studies in other autoimmune diseases may help clarify the relevance of H370N and rs2476601 in different conditions. Through examination of haplotype structure ( Supplementary  Fig. 6 ) and formal conditional analysis (Supplementary Table 6) , we found that the rare variants highlighted in IL18RAP, MUC19, C1orf106, PTPN22 and CUL2 are independent of the common associated GWAS variants. Specifically, the rare variants at IL18RAP and MUC19 reside on the common higher-risk background but confer independently significant risk, the rare variants at PTPN22 and C1orf106 occur on the common low-risk background and are therefore independent, and the rare variant at CUL2 is protective and in weak LD with common-risk variants at that locus.
Heritability estimates of rare associated variants
We estimated the fraction of additive genetic variance explained using the liability threshold model 40, 41 , which assumes an additive effect at each locus and shifts the mean of a normal distribution of disease liability for each genotype class. We assumed a prevalence of Crohn's disease of 4 per 1,000 and a total narrow-sense heritability of 50% (ref. 42) . We estimate that the discovered rare and low-frequency variants associated with Crohn's disease in this study contribute another 1-2% genetic variance over all populations and 2-3% genetic variance to the Ashkenazi Jewish population (Supplementary Table 7) .
DISCUSSION
Genome-wide association has been highly successful in IBD, with 99 confirmed associations providing new insight into disease biology. However, it is the ~75% of heritability yet to be explained that fuels most debate in human genetics. NGS offers potential insights into both the biology and the heritable component explained by GWAS results by completing the allelic spectrum of functional alleles in cases and controls, including rare variation.
Using a targeted pooled approach, we carried out an efficient and cost-effective scan for rare and low-frequency polymorphisms in genes from regions identified as relevant through GWAS. After extensive follow-up genotyping, we identified highly significant variants at CARD9, NOD2, CUL2 and IL18RAP that contribute to risk independently of previously defined variants at these loci, and we showed the functionality of the newly implicated NOD2 variants. We report additional protective variants at IL23R and identify nominally significant variants in MUC19, PTPN22 and C1orf106 more frequently than expected by chance.
The results of this experiment are relevant to ongoing debates in human genetics. Although we found little support for the hypothesis that common-variant associations are simply an indirect LD-driven by-product of higher penetrance rare alleles, additional independently acting low-frequency alleles in genes implicated by common-variant association are documented. In the case of the CARD9 splice variant, this newly discovered allele explains more of the overall population variance in risk than does the common S12N variant (about 0.3% and 0.2%, respectively). If these observations become commonplace through Figure 4 Functional analyses of NOD2 variants. (a) Schematic of NOD2 protein domains and localization. (b) HEK293T cells were transfected with NOD2 constructs and fixed using 4% paraformaldehyde at 24 h after transfection. Cells were then subjected to immunofluorescent staining to detect NOD2 and fluorescence was collected using a confocal microscope. Image gallery of a single confocal section. (c) HEK293T cells were transfected with NOD2 constructs and reporter plasmids encoding firefly luciferase cloned under a promoter containing NF-κB elements and with a plasmid encoding renilla luciferase as a transfection control. After 24 h, cells were stimulated with MDP−l-alanine−l-glutamine (LL) or MDP−l-alanine−d-glutamine (LD) (10 µg/ml) for 6 h. Transcriptional activation was quantified by ratios of firefly luciferase activity to renilla luciferase activity. Data were normalized to unstimulated condition with empty vector transfection. Statistical analyses were carried out using Student's t-test (*P < 0.05). Error bars represent 95% CI for fold activation. (d) Cell lysates were also collected and subjected to western blot analysis to detect NOD2 and actin expression levels. Scale bars, 10 µm. A r t i c l e s available technology, they may help make the debates about common versus rare variation biologically irrelevant. As in many quantitative traits and Mendelian disorders, we observed common alleles of modest effect and rarer alleles with more considerable impact coexisting in the same genes, with both types of variation providing insight into the same disease biology. More than simply increasing variance explained, these results will likely be of great value to functional biology. In addition to the functional confirmation of NOD2 alleles, the identification of a new CARD9 isoform that strongly protects against disease development provides a way to study disease biology and a model that could be mimicked therapeutically. Finally, our study suggests that additional variants should be routinely searched for by thorough sequencing of genes within significantly associated regions in GWAS in large sets of cases and appropriate controls, not simply to expand incrementally the variance explained, but to identify specific alleles that may substantially advance our understanding of the functional role of each gene.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
